Ignota Labs Raises $6.9M Seed Round to Revive Failed Drug Candidates Using AI

Ignota Labs is tackling a $400B annual loss in drug development by reviving abandoned projects.

Ignota Labs Raises $6.9M Seed Round to Revive Failed Drug Candidates Using AI
Source: Ignota Labs

Company Name: Ignota Labs
Location: Cambridge, UK
Industry: Health Tech

Funding Details:

  • Amount: $6.9M (Seed Round)
  • Investors:
    • Lead: Montage Ventures, AIX Ventures
    • Participants: Modi Ventures, Blue Wire Capital, Gaingels

Purpose of Investment:

  • Expand pipeline by acquiring additional distressed drug assets.
  • Advance first asset (PDE9A inhibitor) into early-stage clinical trials.

Leadership:

Product:

Ignota Labs specializes in rescuing promising but failing drugs, leveraging AI to overcome toxicity and safety issues that lead to costly clinical failures.

  • Proprietary SAFEPATH Platform – Uses deep learning, cheminformatics, bioinformatics, and multimodal data analysis to:
    • Uncover mechanisms behind drug toxicity.
    • Explain why and how safety issues occur.
    • Deliver actionable insights to refine or repurpose drug candidates.

About the Company:

With over 50% of clinical trials failing due to safety concerns, Ignota Labs is tackling a $400B annual loss in drug development by reviving abandoned projects. The company is building a pipeline of rescued drug candidates, co-developing assets, and accelerating the delivery of life-saving treatments to patients in need.

Read next